Usefulness of recombinant ?-gliadin 1 for identifying patients with celiac disease and monitoring adherence to a gluten-free diet - 04/12/15
Abstract |
Background |
Celiac disease (CD) is an inflammatory disease of the small intestine caused by an immunologic hypersensitivity reaction to dietary wheat gluten.
Objectives |
We sought to clone, express, and perform IgA epitope mapping of a CD-specific wheat antigen and to study its usefulness for identifying patients with CD and monitoring adherence to a gluten-free diet.
Methods |
A synthetic gene coding for γ-gliadin 1 (GG1) was expressed in Escherichia coli. Recombinant γ-gliadin 1 (rGG1) was purified and characterized biochemically, structurally, and immunologically by using sera from patients with CD and control subjects. Overlapping GG1 peptides were synthesized for IgA and IgG epitope mapping. GG1 and peptide-specific antibodies were raised for tracing GG1 in cereals and dietary wheat products and to study its resistance to digestion.
Results |
rGG1 was expressed and purified. rGG1-based IgA ELISAs performed in populations of patients with CD and control subjects showed a specificity of 92.9%, which was higher than that of gliadin extract (e). Furthermore, it allowed monitoring of adherence to a gluten-free diet in patients. A 26-amino-acid peptide from the proline-glutamine–rich repetitive N-terminal region was identified as the immunodominant IgA epitope. GG1-related antigens were found in rye, barley, and spelt but not in oat, rice, or maize. GG1 was detected in dietary wheat products after baking, and in particular, the major IgA epitope–containing region was resistant against digestion.
Conclusions |
rGG1 and its epitope might be useful for identifying patients with CD, monitoring treatment, and studying the pathomechanisms of CD and development of preventive and therapeutic strategies.
El texto completo de este artículo está disponible en PDF.Key words : Celiac disease, cloning, recombinant gamma gliadin 1, epitope
Abbreviations used : AGA, AUC, CD, DGP, EMA, GFD, GG1, ID, MALDI-TOF, NCBI, PBST, rGG1, tTG2
Esquema
| Supported by the FWF-funded PhD program IAI DK W1212 and the Medical University of Vienna and in part by a research grant from Phadia/Thermo Fisher Scientific, Uppsala, Sweden. |
|
| Disclosure of potential conflict of interest: R. Atreya has consultant arrangements with AbbVie, Takeda, InDex, and MSD Sharp & Dohme and has received research support from the German Research Council. M. F. Neurath has consultancy arrangements with MSD, Giuliani, Pentax, InDex Pharmaceuticals, Shire, and Tillotts Pharma; has received research support from the German Research Council and German Cancer Aid; has received payment for lectures from AbbVie, Boehringer Ingelheim, Celgene Corporation, Falk Foundation, Ferring, MSD, Janssen, and Takeda; has a patent for anti–IL-12 therapy in patients with Crohn disease; and receives royalties from Thieme and VG Wort. H. Vogelsang has received research support from the Austrian Science Fund. R. Valenta has received research support and a consulting fee or honorarium from Thermo Fisher Scientific, has consultancy arrangements from Biomay AG and Fresenius Medical Care, and has received research support from Biomay AG. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 136 - N° 6
P. 1607 - décembre 2015 Regresar al número
Artículo precedente
- Efficacy of baked milk oral immunotherapy in baked milk–reactive allergic patients
- Michael R. Goldberg, Liat Nachshon, Michael Y. Appel, Arnon Elizur, Michael B. Levy, Eli Eisenberg, Hugh A. Sampson, Yitzhak Katz
- An in vivo genetic reversion highlights the crucial role of Myb-Like, SWIRM, and MPN domains 1 (MYSM1) in human hematopoiesis and lymphocyte differentiation
- Tangui Le Guen, Fabien Touzot, Isabelle André-Schmutz, Chantal Lagresle-Peyrou, Benoit France, Laetitia Kermasson, Nathalie Lambert, Capucine Picard, Patrick Nitschke, Wassila Carpentier, Christine Bole-Feysot, Annick Lim, Marina Cavazzana, Isabelle Callebaut, Jean Soulier, Nada Jabado, Alain Fischer, Jean-Pierre de Villartay, Patrick Revy
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?